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Beta-blockers are prescribed as fourth-line treatment 
options for hypertension in South African (SA) 
patients.
[1,2] Withdrawal of chronic β-blockade 
during the perioperative period is associated with 
poor outcomes in non-cardiac surgery patients.
[3]
 
However, acute initiation of β-blockade during the perioperative 
period has also been shown to be associated with a higher risk of 
adverse outcomes following non-cardiac surgery,
[4,5] probably as a 
consequence of perioperative haemodynamic instability modulated 
by acute β-blockade.
[6] A large percentage of SA vascular patients have 
mean blood pressures above the therapeutic target.
[7] Acknowledging 
that poorly controlled hypertension is highly prevalent in the 
SA vascular patient population, it is possible that uncontrolled 
hypertension could further aggravate haemodynamic instability 
caused by acute β-blockade, resulting in high levels of perioperative 
cardiac morbidity and mortality.
Objective
To determine the impact of acute preoperative β-blockade on the 
incidence of perioperative cardiovascular morbidity and all-cause 
mortality in hypertensive SA patients who underwent vascular 
surgery at a tertiary hospital.
Methods
Study design, setting, and patients
This study consisted of two separate case-control analyses, and was a sub-
study of the South African Vascular Surgical-Cardiac Risk Index (SAVS-
CRI) study.
[8] Briefly, the SAVS-CRI study was a prospective cohort study 
conducted at Inkosi Albert Luthuli Central Hospital in Durban, SA, 
which sought to determine risk factors for perioperative major adverse 
cardiovascular events (MACEs) in vascular surgery patients. The study 
was approved by the University of KwaZulu-Natal Biomedical Research 
Ethics Committee (Protocol BF068/07, BCA117/010). A registry of 
consenting adult patients who underwent elective vascular surgery at 
the hospital between February 2008 and March 2011 was created to 
prospectively collect data related to demographic variables, medication 
use, and established risk factors for the primary outcome of this study, 
perioperative MACEs in vascular surgery patients receiving acute 
preoperative β-blockade. We did not exclude patients with respiratory, 
endocrine or neurological disorders from the registry, except when 
they were unable to provide appropriate written informed consent for 
inclusion in the registry. A MACE was defined as a composite of all-
cause mortality within 30 days of surgery or a perioperative troponin-I 
leak of ≥0.1 ng/ml that occurred within 3 days after a patient’s surgery. 
We defined patients receiving acute preoperative β-blockade as those 
who had a β-blocker prescribed or administered during the same 
hospital admission for surgery. The definitions of established risk factors 
for adverse perioperative outcomes used in the SAVS-CRI study
[8]
 and 
in this study were adopted from the study of Lee et al.
[9]
 We filtered 
the SAVS-CRI cohort for vascular surgery patients with a history of 
hypertension (patients diagnosed with hypertension by a doctor, or 
patients taking antihypertensive medications).
Matching of cases and controls
Propensity scores for all hypertensive patients were calculated following 
matching according to demographic factors (age, gender), clinical 
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factors (ischaemic heart disease, diabetes, 
cerebrovascular disease, renal impairment and 
congestive heart failure), and antihypertensive 
medication use (angiotensin-converting 
enzyme inhibitors and calcium channel 
blockers, but not β-blockers). For the 
perioperative MACEs case-control analysis, 
cases were defined as patients who suffered 
perioperative MACEs, while controls were 
defined as patients who did not suffer 
perioperative MACEs. Patients were matched 
in a 1:1 case-to-control ratio based on similar 
propensity scores, resulting in a total of 99 
matched pairs that were included in the 
analysis for the MACEs case-control analysis.
We also conducted a case-control 
analysis to determine the impact of acute 
preoperative β-blockade on the incidence 
of perioperative troponin-I leak alone in 
hypertensive SA vascular surgery patients. 
Patients were matched using a methodology 
similar to that described for the MACEs 
case-control analysis, resulting in a total of 
86 matched pairs that were included in the 
analysis for the perioperative troponin-I leak 
case-control analysis.
Statistical analysis
Categorical data were analysed using χ2, 
Fisher’s exact or McNemar’s tests, where 
appropriate. Student’s t-tests were used to 
analyse continuous data. A binary logistic 
regression model was used to determine 
whether acute preoperative β-blockade 
was a predictor of perioperative MACEs or 
perioperative troponin-I leak. Results for 
the categorical data analysis are presented 
as frequencies and percentages, while results 
for the binary logistic regression analyses 
are presented as odds ratios (ORs) with 
95% confidence intervals (CIs). Any p-value 
<0.05 was considered to be statistically 
significant. All statistical analyses, including 
the derivation of the propensity scores for 
each patient, were performed using the 
Statistical Package for the Social Sciences 
(SPSS), version 21 (SPSS Inc., USA).
Results
The study profiles for both the perioperative 
MACEs and the perioperative troponin-I 
leak case-control analyses are illustrated 
in Fig. 1. A total of 540/788 patients 
from the SAVS-CRI cohort (68.5%) were 
hypertensive and were screened for inclusion 
in the matching process. There were 103 
perioperative MACEs and 89 perioperative 
troponin-I leaks in these 540 patients. Four 
patients with perioperative MACEs and 3 
with perioperative troponin-I leak were 
excluded owing to missing comorbidity 
data, namely preoperative serum creatinine 
measurements, which were required to match 
cases and controls based on the criterion 
for renal impairment of serum creatinine 
>177 μmol/l as defined by Lee et al.
[9] The 
final study population for the perioperative 
MACEs case-control analysis therefore 
consisted of 99 matched pairs of cases and 
controls (n=198). A total of 31/99 patients 
(31.4%) had died within 30 days of surgery, 
788 adult vascular surgery
partients in the SAVS-CRI cohort
540 hypertensive patients
103 patients with perioperative
MACEs









99 patients with perioperative
MACEs (4 patients excluded:
missing data) matched with 99
patients without perioperative
MACEs
86 patients with perioperative
troponin-I leak (3 patients
excluded: missing data) matched
with 86 patients without
perioperative troponin-I leak
Fig. 1. Study profiles of the perioperative MACEs and perioperative troponin-I leak case-control analyses.
Table 1. Clinical characteristics of cases and controls in the perioperative MACEs case-control analysis
Clinical characteristic All patients (N=198)
Patients with perioperative 
MACEs (cases, N=99)
Patients without perioperative 
MACEs (controls, N=99) p-value*
Male gender, n (%) 103 (52.0) 53 (53.5) 50 (50.5) 0.670
Age (years), mean (SD) 64.4 (11.4) 64.6 (12.3) 64.2 (10.3) 0.793
Ischaemic heart disease, n (%) 119 (60.1) 57 (57.6) 62 (62.6) 0.468
Diabetes, n (%) 134 (67.7) 64 (64.6) 70 (70.7) 0.362
Congestive heart failure, n (%) 21 (10.6) 10 (10.1) 11 (11.1) 0.817
Renal impairment, n (%) 8 (4.0) 4 (4.0) 4 (4.0) 1.000
History of cerebrovascular accident, n (%) 42 (21.2) 21 (21.2) 21 (21.2) 1.000
High-risk surgical procedures, n (%) 28 (14.1) 15 (15.2) 13 (13.1) 0.683
Acute preoperative aspirin use, n (%) 190 (96.0) 94 (94.9) 96 (97.0) 0.721
Acute preoperative calcium channel 
blocker use, n (%)
69 (34.8) 37 (37.4) 32 (32.3) 0.456
Acute preoperative angiotensin-
converting enzyme inhibitor use, n (%)
139 (70.2) 70 (70.7) 69 (69.7) 0.877
Acute preoperative β-blocker use, n (%) 100 (50.5) 65 (65.7) 35 (35.4) <0.001
SD = standard deviation.
p<0.05 was considered a statistically significant result.
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with perioperative troponin leaks noted in 
15 of these cases (48.4%). The final study 
population for the perioperative troponin-I 
leak case-control analysis consisted of 86 
matched pairs of cases and controls (n=172).
The clinical characteristics of the case 
and control groups in the perioperative 
MACEs case-control analysis are shown 
in Table 1. With the exception of acute 
preoperative β-blocker use (p<0.001), no 
statistically significant results were noted 
on χ2 testing between any other clinical 
characteristics in the case and control 
groups, indicating appropriate matching 
of the individual cases and corresponding 
controls. The results of McNemar’s test 
also showed that the association between 
acute preoperative β-blocker use and 
perioperative MACEs was statistically 
significant in this study (p<0.001). 
When entered into a logistic regression 
equation, acute preoperative β-blocker use 
was associated with an almost 3.5-fold 
increased risk of developing perioperative 
MACEs following vascular surgery in 
hypertensive SA patients (OR 3.496; 95% 
CI 1.948 - 6.273; p<0.001).
Table 2 shows the clinical characteristics 
of cases and controls in the perioperative 
troponin-I leak case-control analysis. As 
with the perioperative MACEs case-
control analysis, cases and controls in the 
perioperative troponin-I leak case-control 
analysis appeared to be efficiently matched 
with regard to clinical comorbidities, 
procedural risk, and calcium channel 
blocker and angiotensin-converting enzyme 
inhibitor use. A statistically significant 
association between preoperative acute 
β-blockade and perioperative troponin-I 
leak was observed following χ2 testing 
(p<0.001). When case-control pairs were 
analysed via McNemar’s test, an association 
between acute preoperative β-blockade and 
perioperative troponin-I leak was observed 
(p<0.001). When entered into a logistic 
regression equation, acute preoperative 
β-blocker use was associated with an 
increased risk of developing perioperative 
troponin-I leak following vascular surgery 
in hypertensive SA patients (OR 5.962; 95% 
CI 3.085 - 11.52; p<0.001). A description of 
acute preoperative β-blocker use for both 
case-control analyses is presented in Table 3.
Table 2. Clinical characteristics of cases and controls in the perioperative troponin-I leak case-control analysis 
Clinical characteristic All patients (N=172)
Patients with perioperative 
troponin-I leak (cases, N=86)
Patients without perioperative 
troponin-I leak (controls, N=86) p-value*
Male gender, n (%) 87 (50.6) 45 (52.3) 42 (48.8) 0.647
Age (years), mean (SD) 63.8 (11.1) 64.2 (12.2) 63.4 (9.9) 0.657
Ischaemic heart disease, n (%) 109 (63.4) 53 (61.6) 56 (65.1) 0.635
Diabetes, n (%) 121 (70.3) 58 (67.4) 63 (73.3) 0.404
Congestive heart failure, n (%) 18 (10.5) 9 (10.5) 9 (10.5) 1.000
Renal impairment, n (%) 6 (3.5) 3 (3.5) 3 (3.5) 1.000
History of cerebrovascular accident,  
n (%)
39 (22.7) 20 (23.3) 19 (22.1) 0.856
High-risk surgical procedures, n (%) 27 (15.7) 14 (16.3) 13 (15.1) 0.834
Acute preoperative aspirin use, n (%) 165 (95.9) 81 (94.2) 84 (97.7) 0.443
Acute preoperative calcium channel 
blocker use, n (%)
58 (33.7) 32 (37.2) 26 (30.2) 0.333
Acute preoperative angiotensin-
converting enzyme inhibitor use, n (%)
114 (66.3) 59 (68.6) 55 (64.0) 0.519
Acute preoperative β-blocker use, n (%) 88 (51.2) 62 (72.1) 26 (30.2) <0.001
SD = standard deviation.
*p<0.05 was considered a statistically significant result.
Table 3. Description of acute preoperative β-blocker use in both case-control analyses 
Perioperative MACEs case-control analysis Perioperative troponin-I leak case-control analysis











Atenolol only, n (%) 80 (80.0) 53 (81.5) 27 (77.1) 71 (80.7) 49 (79.0) 22 (84.6)
Atenolol + 
carvedilol, n (%)
5 (5.0) 3 (4.6) 2 (5.7) 5 (5.7) 3 (4.8) 2 (7.7)
Atenolol + labetalol, 
n (%)
2 (2.0) 1 (1.5) 1 (2.9) 1 (1.1) 1 (1.6) 0 (0.0)
Carvedilol only,  
n (%)
12 (12.0) 7 (10.9) 5 (14.3) 10 (11.4) 8 (13.0) 2 (7.7)
Labetalol only, n (%) 1 (1.0) 1 (1.5) 0 (0.0) 1 (1.1) 1 (1.6) 0 (0.0)
Total, n (%) 100 (100.0) 65 (100.0) 35 (100.0) 88 (100.0) 62 (100.0) 26 (100.0)
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Discussion
We found acute preoperative β-blockade to be an independent 
predictor of perioperative cardiac morbidity (as evidenced by 
perioperative troponin-I measurements) and all-cause mortality in 
hypertensive SA vascular surgery patients.
We suspect that these results are related to perioperative 
haemodynamic instability. Hypotension is a common perioperative 
complication in vascular surgery patients with a history of poorly 
controlled hypertension, with a study by Charlson et al.
[10]
 reporting 
a higher incidence of perioperative hypotension in patients who had 
preoperative mean arterial blood pressures ≥110 mmHg than in those 
with preoperative mean arterial blood pressures of <100 mmHg. In 
another study by Charlson et al.,
[11]
 a decrease in mean arterial blood 
pressure of ≥20 mmHg for ≥5 minutes was associated with an increased 
incidence of perioperative cardiac complications in non-cardiac 
surgery patients. Perioperative hypotension is therefore an important 
determinant of perioperative cardiac outcomes in non-cardiac surgery 
patients, in particular those with poorly controlled hypertension.
Acute preoperative β-blockade may further aggravate the 
haemodynamic instability associated with a history of poorly 
controlled hypertension. The POISE-I study was a randomised 
controlled trial comparing the effect of acutely administered, 
extended-release β-blocker (metoprolol succinate) with that of 
placebo on the 30-day risk of major cardiovascular events in patients 
with, or at risk of, atherosclerotic disease who were undergoing 
non-cardiac surgery.
[12] In this study, patients randomised to 
acute preoperative β-blockade had significantly more hypotension. 
Furthermore, hypotension was associated with perioperative 
mortality (hazard ratio (HR) 1.33; 95% CI 1.03 - 1.74; p=0.0317). 
An analysis of the causation of perioperative deaths in the POISE-I 
study suggested that hypotension was partly associated with some 
of the mortality.
[12]
Although the POISE-I study
[12]
 did not find perioperative 
hypotension to be associated with perioperative myocardial infarction 
in non-cardiac surgery patients, the POISE-II study,
[13]
 which 
was a randomised controlled study of clonidine v. placebo, found 
clinically important hypotension to be independently associated with 
perioperative myocardial infarction (HR 1.37; 95% CI 1.16 - 1.62; 
p<0.001).
[13]
It is therefore likely that our study population of hypertensive 
vascular surgery patients with previously documented poorly 
controlled hypertension may have been predisposed towards 
perioperative hypotension, which could have been further 
exacerbated by acute preoperative β-blockade, resulting in the 
observed increased incidence of perioperative cardiac morbidity and 
all-cause mortality. These findings have important implications for 
primary and secondary prevention of myocardial ischaemia in the 
perioperative period in hypertensive vascular surgery patients.
Study limitations
Our study had several limitations. We only collected data related to 
perioperative cardiac outcomes and all-cause mortality during this 
study, and we were unable to evaluate the impact of acute preoperative 
β-blockade on other perioperative complications that might have 
occurred, such as stroke and clinically important hypotension. 
Based on results from POISE-I,
[12] it is likely that acute preoperative 
β-blockade may also further increase perioperative stroke risk in 
SA hypertensive vascular surgical patients. We did not collect data 
related to chronic obstructive airway disease and were therefore 
unable to control for this factor in either of the case-control analyses. 
We also did not collect data related to neurological disorders other 
than cerebrovascular disease. While we did not collect data related to 
diabetes treatment, it is likely that diabetic patients were placed on an 
insulin sliding scale preoperatively, in line with current local practice. 
Although we did not collect information related to the actual dosage 
of the drugs administered to vascular patients in our institution, 
atenolol is commonly prescribed at a dose of 50 mg orally per day, 
labetalol is titrated to effect with heart rate control when patients 
cannot take medications orally, and carvedilol is prescribed for heart 
failure and is up-titrated to the desired effect over a period of time.
In addition, we were unable to access information related to patients’ 
cause of death once they had been discharged from hospital. Another 
limitation is that our patient population was drawn from a single 
tertiary hospital and represented a population with substantial medical 
comorbidity at high-risk for perioperative cardiac complications or 
death, requiring specialist vascular surgery. It is therefore possible that 
the epidemiology of acute preoperative β-blocker administration and 
patient comorbidities in our study population may be different from 
that in patients attending lower-level facilities, or even facilities in 
different geographical locales within SA.
Conclusions
Acute preoperative β-blocker administration was associated with 
an increased risk of perioperative cardiac morbidity and all-cause 
mortality in hypertensive SA vascular surgery patients. A cautious 
approach should be taken when considering initiating acute 
preoperative β-blockade in hypertensive surgical patients.
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